文献速递骨软组织肉瘤与黑色素瘤

晚期皮肤鳞状细胞癌患者特征与治疗模式的回顾性分析:DeCOG非干预性研究结果

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.
PubMed 文献 · Eur J Cancer · 2018-04-14

该回顾性研究纳入德国和奥地利24家医院及诊所2010–2011年诊断的190例晚期皮肤鳞状细胞癌(aSCC)患者,描述其临床病程、治疗管理和预后。结果显示局部晚期患者多数未接受治疗,转移性患者多接受至少一种治疗,仅32例接受系统抗肿瘤治疗且缓解持续时间短,提示该领域存在高度未满足的医疗需求。

要点

  • aSCC诊断中位年龄78岁,60%为转移性,40%为局部晚期。
  • 局部晚期患者59%未接受任何治疗,转移性患者92%接受至少一种治疗。
  • 仅32例接受系统抗肿瘤治疗,多为EGFR抑制剂方案,缓解持续时间短。

核心结论

  • aSCC存在高效且可耐受抗肿瘤治疗的高度未满足需求。
  • 尽管患者年龄较大且合并症多,多数患者仍可期望适合治疗。
  • 该研究为新兴aSCC治疗提供了历史背景。

研究设计与样本

  • 回顾性研究,在德国和奥地利24家医院及医生办公室开展。
  • 晚期SCC包括局部晚期(laSCC)或转移性(mSCC)伴任何类型转移。

主要发现

  • 诊断aSCC时中位年龄78岁。
  • laSCC 76例(40%),mSCC 114例(60%)。
  • laSCC患者中59%未接受任何治疗,mSCC患者中92%至少接受一种治疗。
  • 仅32例(29例mSCC,3例laSCC)接受系统抗肿瘤治疗,多为EGFR抑制剂方案。
  • 缓解持续时间短:laSCC患者平均17个月,mSCC患者平均3个月;仅2例完全缓解,27%部分缓解,43%疾病稳定。

临床怎么用

  • 临床实践中应评估aSCC患者年龄和合并症,但多数患者仍可适合治疗。
  • 局部晚期患者治疗选择有限,需关注未满足需求。
  • 转移性患者常接受系统治疗,但现有方案缓解持续时间短。

局限性

  • 回顾性研究设计。
  • 数据来自2010–2011年诊断患者,反映历史治疗模式。
  • 样本量有限(190例),仅32例接受系统治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor received FDA breakthrough therapy designation. The aim of the study was to describe the clinical course, therapeutic management and prognosis of aSCC under real-life conditions. PATIENTS AND METHODS: In a retrospective study performed in 24 German and Austrian hospitals and doctor's offices, patient and tumour characteristics of patients diagnosed with aSCC between January 1, 2010 and December 31, 2011 and their disease course was documented. Advanced SCC comprised either locally advanced SCCs (laSCC) or metastatic SCCs (mSCC) with any kind of metastatic spread. RESULTS: Data of 190 patients with aSCC were analysed. Median age at time of diagnosis of aSCC was 78 years. LaSCC was diagnosed in 76 patients (40%), 114 patients (60%) had mSCC. Once diagnosed with laSCC, most patients (59%) did not receive any therapy, whereas in 92% of mSCC patients at least one type of therapy was performed. Only 32 patients (29 mSCC, 3 laSCC) received systemic antitumour therapies, mostly EGFR inhibitor-based regimens. Mean duration of response was short (17-months laSCC patients, 3-months mSCC patients). Only 2 patients achieved a complete response, 27% had a partial response, 43% disease stabilisation. At diagnosis of aSCC, ECOG status was 0-1 in most patients. Non-malignant comorbidities influenced the decision on SCC-specific therapy in 39 patients (21%). CONCLUSIONS: Our data show the high medical need for efficient and tolerable antitumour therapies and demonstrate that despite older age and comorbidities, most patients can be expected to be fit for treatment. This study provides a historical context for emerging aSCC treatments.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018. PMID: 29665511. doi:10.1016/j.ejca.2018.01.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。